Neogenomics
NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing
Doctors ordering NeoGenomics Compass test packages will have the option of including Adaptive's ClonoSeq minimal residual disease assay.
The company believes that it has threaded the needle in terms of providing the maximum of necessary information to clinicians, while maintaining a rapid turnaround time.
NeoGenomics Wins New York State Approval for Solid Tumor, Lung Cancer NGS Tests
Although the approval is conditional, the company can now offer the tests for physicians and patients in the state.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
Jul 31, 2023
Natera Sues NeoGenomics for Patent Infringement
Feb 15, 2023
Dec 12, 2022
Feb 17, 2022
Nov 4, 2021